{"id":"W4405096070","doi":"10.1182/blood-2024-203060","title":"PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Tolerability; Protein arginine methyltransferase 5; Medicine; Hematologic Neoplasms; Refractory (planetary science); Internal medicine; Phases of clinical research; Methyltransferase; Pharmacology; Oncology; Adverse effect; Clinical trial; Chemistry; Transplantation; Methylation; Biology; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008035116,0.0002294835,0.0003279217,0.00008948355,0.00007774065,0.00002657745,0.0001352457,0.0001003284,0.00000961884],"category_scores_gemma":[0.0001336403,0.0001577966,0.00006113196,0.0003424288,0.0001145273,0.00001039503,0.0001279049,0.0001588354,0.000001692406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002745866,"about_ca_system_score_gemma":0.0002073302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004912233,"about_ca_topic_score_gemma":0.0002138753,"domain_scores_codex":[0.9981707,0.0002477837,0.0004562552,0.00056545,0.0002675185,0.0002922555],"domain_scores_gemma":[0.9992692,0.00004273819,0.00004988071,0.0004666585,0.00008603184,0.0000855265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001409516,0.003970169,0.001975093,0.0001347323,0.00028272,0.00003407277,0.002189976,0.0007048708,0.9872801,0.00005469709,0.00001564327,0.001948416],"study_design_scores_gemma":[0.01287893,0.01293555,0.01245763,0.0003804509,0.0004127247,0.00004255486,0.0003962927,0.0003246833,0.9592832,0.000140874,0.0003725191,0.0003746208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940923,0.002857602,0.0003016363,0.0004032347,0.00005271226,0.002222183,0.00002553193,0.0000247285,0.00002007156],"genre_scores_gemma":[0.9993859,0.00004729025,0.0001901556,0.00002362865,0.00005836492,0.0001973407,0.00001931697,0.0000293769,0.00004863508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02799691,"threshold_uncertainty_score":0.6434757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01645209202164249,"score_gpt":0.2911731206852303,"score_spread":0.2747210286635878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}